Article
Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.
Clinical lung cancer - 1 Sept 2016
Lin Yen-Ting, Yu Chong-Jen, Yang James Chih-Hsin, Shih Jin-Yuan
Abstract excerpt
BACKGROUND: Secondary anaplastic lymphoma kinase (ALK) mutation may occur in patients with advanced ALK-positive non-small cell lung cancer treated with ALK inhibitors, but its nature is not well-known. PATIENTS AND METHODS: We analyzed tumor specimens after the failure of treatment with ALK inhibitor(s) (crizotinib, alectinib, and ceritinib) for secondary ALK kinase domain mutation, EGFR, K-ras, and PIK3CA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.